Retatrutide

An investigational peptide from Eli Lilly that acts on three hormone receptors. Phase 3 trials reported their first results in 2026.

Level of evidence

Clinical trials — controlled human studies

What it is

Retatrutide is a single peptide designed to activate three receptors: GIP, GLP-1 and glucagon. It is developed by Eli Lilly under the code LY3437943.

State of the research

A phase 2 trial was published in 2023 (New England Journal of Medicine). Phase 3 trials (TRIUMPH programme) reported positive topline results in 2026. Its safety profile in humans is still being established.

Sources

PubMed — retatrutide
Epocrates — Retatrutide heads toward FDA filing (July 2026)

Last reviewed: October 2026

Summaries of published scientific literature, for information and laboratory research only. They do not describe uses of our products, are not medical advice and do not imply that any compound is safe or effective in humans. Our products are not for human or animal consumption.